Plus Therapeutics Inc Stock Price, News & Analysis

Plus Therapeutics (Nasdaq: PSTV) announced it will present interim data from its ReSPECT™ Phase 1 clinical trial of Rhenium-186 NanoLiposome (186RNL) for recurrent glioblastoma at the Society for Neuro-Oncology Annual Meeting, scheduled for November 19, 2021. The presentation will cover the safety and feasibility of this innovative treatment. Dr. Andrew Brenner, the principal investigator, will lead the session, highlighting potential advancements in oncology therapeutics aimed at improving patient outcomes.

Plus Therapeutics (Nasdaq: PSTV) announced that Marc H. Hedrick, M.D., President and CEO, will present at the Benzinga Healthcare Small Cap Conference on September 30, 2021, at 4:20 p.m. ET. The presentation will provide an overview of the company's innovative, targeted radiotherapeutics aimed at rare cancers. Attendees can register for the presentation and one-on-one meetings through the Benzinga website. A replay will be available on Plus Therapeutics' Investor Relations page. The company is focused on developing nanoliposome-encapsulated drugs to enhance safety and efficacy for patients.

Plus Therapeutics, Inc. (Nasdaq: PSTV) will present data on its investigational Rhenium-186 NanoLiposome (¹⁸⁶RNL) for treating recurrent glioblastoma at the ASTRO 2021 Annual Meeting, scheduled for October 24-27 in Chicago. The presentation, titled "Image-guided Rhenium-186 NanoLiposome brachytherapy in the treatment of recurrent glioblastoma," will occur on October 27 at 1:00 p.m. CT. The abstract will be available online on October 22, and the poster will be accessible on the Company’s website. Plus Therapeutics focuses on targeted radiotherapeutics for rare cancers.

Plus Therapeutics (PSTV) announced the appointment of Dr. Norman LaFrance as Chief Medical Officer and Senior Vice President, effective December 8, 2021. Dr. LaFrance brings nearly 40 years of experience in nuclear medicine and pharmaceuticals, with expertise in radiotherapeutics and drug development. His previous roles include Chief Medical Officer at Jubilant Pharma and Global Chief Medical Officer at IBA Molecular. CEO Marc Hedrick expressed confidence that Dr. LaFrance's extensive background will enhance the company's pipeline and support its long-term goals in addressing unmet medical needs in cancer treatment.

Plus Therapeutics (Nasdaq: PSTV) announced that its CEO, Marc H. Hedrick M.D., will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13 to 15, 2021. This virtual event offers investors a chance to engage with the company's management. A webcast of the presentation will be available on-demand starting September 13, 2021, at 7:00 a.m. on the company's website. Plus Therapeutics focuses on developing innovative radiotherapeutics targeting rare cancers using a unique nanotechnology platform.

Plus Therapeutics (PSTV) has partnered with RadioMedix for the commercial production of Rhenium-186 NanoLiposome (186RNL), a targeted radiotherapeutic for recurrent glioblastoma. This strategic alliance aims to ensure cGMP compliance, facilitating clinical studies slated for mid-2022. 186RNL is designed to effectively deliver radiation to central nervous system tumors. Plus Therapeutics is currently conducting a Phase 1 clinical trial for recurrent GBM, leveraging NIH support.

Plus Therapeutics has reported promising data from its ReSPECT™ Phase 1 trial for Rhenium-186 NanoLiposome (¹⁸⁶RNL) in treating recurrent glioblastoma. The investigational drug demonstrated good tolerance at high radiation doses, outperforming standard therapies. Key findings include a mean dose of 392 Gy delivered safely, with no serious adverse events noted. The company plans to expand research into pediatric brain tumors, starting a Phase 1 study by mid-2022. The overall response rate will be a primary endpoint in the upcoming trials.

Plus Therapeutics (PSTV) recently presented promising preclinical data supporting its FDA IND application for Rhenium-186 Nanoliposome (186RNL) targeted radiotherapy aimed at treating leptomeningeal metastases (LM). The data, showcased at the Society for Neuro-Oncology's conference, indicated minimal toxicity and significant efficacy in animal models. Plans for a Phase 1 dose escalation clinical trial with patient accrual expected in Q4 2021 were also outlined. The trial will evaluate the treatment's safety and efficacy in patients previously treated for breast or non-small cell lung cancer with LM.

Plus Therapeutics, Inc. (Nasdaq: PSTV) announced it will present data on Rhenium-186 NanoLiposome from its Phase 1 ReSPECT™ trial for recurrent glioblastoma at the American Association of Neurological Surgeons 2021 Annual Scientific Meeting, held virtually from August 21-25, 2021. The presentation titled "A two-part, Phase 1 study of Rhenium-186 NanoLiposome" will be made available on-demand beginning August 21. Lead presenter Michael G. DeCuypere, MD, PhD, will provide insights on the study's findings, which aim to enhance treatment for rare cancers.